Search


PDF Archive search engine
Last database update: 14 May at 16:54 - Around 76000 files indexed.


Show results per page

Results for «mesothelioma»:


Total: 11 results - 0.024 seconds

CV2016 Updated 100%

The research has been focused on mesothelioma, an asbestos-related cancer, but recently also lung and gastric cancer.

https://www.pdf-archive.com/2018/04/22/cv2016-updated/

22/04/2018 www.pdf-archive.com

ESMO-Preceptorship-on-Lung-Cancer-Manchester-2020-Programme.ocr 88%

Fiona Blackhall, United Kingdom Enriqueta Felip, Spain Raffaele Califano, United Kingdom LEARNING OBJECTIVES To To To To To To To To learn about the evidence-base for lung cancer screening and novel diagnostic modalities learn about the management of early stage NSCLC and use of adjuvant treatments understand the role of m ulti-m odality treatment in locally advanced NSCLC and limited stage SCLC learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC understand the role of im m une-checkpoint blockade for lung cancer and to learn about novel im munotherapies learn about treatment of NSCLC with oligom etastatic disease learn about the systemic treatment of mesothelioma and SCLC learn about the role of supportive and palliative care for thoracic malignancies Wednesday, 11 March 2020 08:15-09:15 60’ Registration 09:15-10:55 100 SESSION 1 Screening and diagnostics for lung cancer 40’ Lung cancer screening Chairs:

https://www.pdf-archive.com/2020/01/17/esmo-preceptorship-on-lung-cancer-manchester-2020-programmeocr/

17/01/2020 www.pdf-archive.com

2017DBS Antibody Flyer 102017 web 84%

It is useful in differentiating lung adenocarcinoma (+) and mesothelioma (-), as well as tumors of unknown origin in liver cancers and distinguishing cholangiocarcinoma (+) from hepatocellular carcinomas (-).

https://www.pdf-archive.com/2017/10/30/2017dbs-antibody-flyer-102017-web/

30/10/2017 www.pdf-archive.com

Scherpereel Arnaud (3) 81%

He was previously the elected Chair of the Pleural and Mediastinal Tumors Group of the TOA of the ERS for 3 years, and the Chair of the 20082009 ERS/ESTS Taskforce to establish guidelines for the management of malignant mesothelioma.

https://www.pdf-archive.com/2016/08/18/scherpereel-arnaud-3/

18/08/2016 www.pdf-archive.com

ER1234 69%

THE PROMISE AND THE PROBLEMS/ ALEX LESOKHIN, MEMORIAL SLOAN KETTERING CANCER CENTER, NEW YORK, USA 11.011.20 A NEW APPROACH FOR PANCREATIC CANCER BIOMARKER DISCOVERY USING PEPTIDOME/ DUAN CHEN, NTNU, TRONDHEIM, NORWAY 11.20- 11.40 DISCOVERY OF HYPERACETYLATED HMGB1 AS A BLOOD DIAGNOSTIC IN MESOTHELIOMA/ HAINING YANG, UNIVERSITY OF HAWAII, HONOLULU, USA 11.40- 12.00 MOLECULARLY STRATIFIED TREATMENT FOR MESOTHELIOMA/ HEDY KINDLER, UNIVERSITY OF CHICAGO, USA 12.0- 13.30 LUNCH/POSTER EXHIBITION.

https://www.pdf-archive.com/2019/06/11/er1234/

11/06/2019 www.pdf-archive.com

AMBaird Bio 63%

Translational Research Fellow (Lung, mesothelioma and prostate) PhD, MSc and MD supervision Teaching OTHER POINTS OF NOTE:

https://www.pdf-archive.com/2018/01/01/ambaird-bio/

01/01/2018 www.pdf-archive.com

AGCTS ASSCR 2017 Scientific Program Final 47%

Preclinical and clinical research for malignant mesothelioma with gene medicine and bisphosphonates.

https://www.pdf-archive.com/2017/05/04/agcts-asscr-2017-scientific-program-final/

04/05/2017 www.pdf-archive.com

2534 - MD Anderson Cancer Center Madrid- Pathology Meeting - program 47%

integrated diagnosis paves the way to precision medicine 12:15 - 12:45 New insights into the molecular pathology of lobular breast carcinoma MEK and PIK3CB inhibitor combination as a promising therapeutical approach for sarcomatoid mesothelioma Dra.

https://www.pdf-archive.com/2018/06/18/untitled-pdf-document/

18/06/2018 www.pdf-archive.com

CVE-MONETTI-FRANCESCO-20170922120319 39%

ECR 2003 Final programme, February 2003, pag 420 "Role of 18F-FDG PET in management of patients with malignant pleural mesothelioma S.Fanti, C.Nanni, C.Pinto, F.Monetti, P.Castellucci, N.Monetti.

https://www.pdf-archive.com/2018/02/01/cve-monetti-francesco-20170922120319/

01/02/2018 www.pdf-archive.com

2016.01.04 08-10-48Reena Nair cv 2016 37%

A Single-blind Randomized Phase 3 Trial of MTA plus Cisplatin versus Cisplatin in Patients with Malignant Pleural Mesothelioma sponsored by Eli-Lilly Ranbaxy Ltd.

https://www.pdf-archive.com/2018/09/11/2016010408-10-48reena-nair-cv-2016/

11/09/2018 www.pdf-archive.com

A0 - Advice to Managers 33%

mesothelioma ­ a cancer of the linings to the lungs and stomach;

https://www.pdf-archive.com/2017/07/07/a0-advice-to-managers/

07/07/2017 www.pdf-archive.com